TAK News & Events

Takeda announced that Julie Kim was officially appointed Takeda's representative director, president and CEO. During the annual general meeting of shareholders, which took place in Osaka, Japan, shareholders elected Kim as a new internal director to the board of directors. Following the vote and conclusion of the meeting, the board of directors appointed her as representative director, president and CEO. Upon conclusion of the meeting, former president and CEO Christophe Weber retired from the company and the board.

Takeda Canada is pleased to announce positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib, an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis. In the LATITUDE Atlas head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified. The study was conducted across eight countries and enrolled 606 participants, including 73 patients across 18 sites in Canada.

Takeda presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton, an oral orexin receptor 2-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1. Oveporexton is designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. These data, along with previously disclosed Phase 3 results, demonstrated improvement across the broad disease spectrum, supporting the potential of oveporexton to redefine the standard of care for NT1. The presentations highlighted results from secondary and exploratory endpoints from two global, multicenter, placebo-controlled studies-FirstLight and RadiantLight-including: Functioning: At all doses, oveporexton significantly improved daily functioning at week 12 compared to placebo across the six domains of the Functional Impacts of Narcolepsy Instrument. Most patients reached or exceeded the published normative domain thresholds, underscoring oveporexton's ability to allow individuals to manage their everyday lives. FINI reflects the domains that are of highest impact for NT1 including tiredness, cognitive functioning, cataplexy, social activities, everyday activities and everyday responsibilities. Cognition: Oveporexton improved cognitive symptoms associated with NT1 compared to placebo, as measured using objective neuropsychological tests of attention, executive function and memory along with patient-reported measures. On the FINI Cognitive Function domain, approximately 70% of patients across all doses reported no significant cognitive difficulties compared to approximately 15% of patients in the placebo arm. Nighttime Sleep: Exploratory endpoints demonstrated that oveporexton improved quality of sleep across both studies. Across all doses, most patients reported no hallucinations or sleep paralysis and most patients on the 2/2mg dose reported meaningful reductions in disturbed nighttime sleep from baseline. Additionally, the timing and pattern of rapid eye movement sleep shifted toward those seen in healthy controls. Takeda will present additional data at the conference, including pooled analyses from previously presented Phase 3 results, data evaluating the impact of oveporexton in reducing microsleeps and an evaluation of the holistic symptom impact of NT1 in the United States.

Takeda announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib, TAK-279, an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis. In the LATITUDE Atlas head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified.